Lupin receives approval for Colesevelam Hydrochloride Tablets; stock gains 1.5%

USFDA has given nod to the pharma major to market a generic equivalent of Welchol Tablets, 625 mg, of Daiichi Sankyo, Inc.

Dec 21, 2020 10:12 IST India Infoline News Service

Lupin
Pharma major Lupin Limited (Lupin) on Friday announced that it has received approval for its Colesevelam Hydrochloride Tablets, 625 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Welchol Tablets, 625 mg, of Daiichi Sankyo, Inc.

Colesevelam Hydrochloride Tablets, 625 mg, are indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. It also reduces LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH).

Colesevelam Hydrochloride Tablets (RLD: Welchol) had an annual sale of approximately USD 159 million in the U.S. (IQVIA MAT September 2020).

At around 10.37 am, Lupin Ltd was trading at Rs986.00 per piece up Rs13.80 or 1.42% from its previous closing of Rs972.20 per piece on the BSE.

Related Story

Open Free Demat Account (Rs699)
Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity